TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: 90 days OGTT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Participant Clinical Benefit Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fears of Recurrence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Total breakthrough opioid consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: score of QoR40 (Quality of Recovery 40)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: percentage of patients with new stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Feasibility of pre-operative conformal radiation therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Posttraumatic Stress Disorder
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline in subject-rated ocular itching scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Best Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of ileostomy bags used per day
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Total work leave time
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in rates of noncompliance
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in rates of tantruming
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in parenting practices
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Improvement in work capacity at anaerobic threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cellular and molecular determinants of IPF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in symptoms related to diastolic heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: score on depression rating scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reliability of continuous glucose monitors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Method Y balance test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detect rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variation from baseline in physical function subscale of the WOMAC
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: change abdominal circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change blood analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Range of Motion of the ankle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analog Scale - Pain Assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cerebral vasoreactivity (CVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percent change from baseline of corneal fluorescein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-72: Area under the concentration-time curve from time zero to 72 hours post-dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart Rate in Beats Per Minute
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of sarcopenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective effects of marijuana
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: health-related self-perceived quality of life
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of repetitions to reach proficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CV risk assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of relapse days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sexual activities with partners
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean Adherence Rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Plasma concentration change of ASP0456
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of acute urinary retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Minimum Efficacious Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health status adjusted utilization of imaging
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean values of diameter, area and number of nuclei and nucleoli
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Approaches to Dementia Questionnaire (ADQ) scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of Patients That Receive Carrier Testing and Have Results to Return
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Diagnostic yield of the histologic core
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion of chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wrinkle severity rating score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of systemic clinical and biological adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients who prematurely discontinued study treatment for reasons linked to general safety
Endpoint domain: Adverse events/effects
Primary endpoint: Diagnostic Accuracy of PET/MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic Accuracy of PET/CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Structural Integrity of Dopaminergic Circuits
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Functional Activity During Executive Function Tasks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Lynch Syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Area under the concentration time curve (AUC) for rifampicin, isoniazid, pyrazinamide, ethambutol, lopinavir and nevirapine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of visceral and subcutaneous fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to Return to Sport
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Chromosomal Aberrations Per 100 Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Micronuclei Per 1000 Binucleated Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of failed sacral lead patients salvaged with pudendal lead
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of Participants Experiencing Any Grade 3 or 4 Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With at Least 1 AE Leading to Study Drug Interruption or Drug Discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Behavioral change
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Observed maximum concentration at steady state (Cmax,ss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of maximum concentration at steady state (tmax,ss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve from zero to the end of the dosing interval at steady state (AUCss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: iPTH value of 100 pg/ml or lower
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Rate of change in myocardial T1 values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Fibroblast Growth Factor 23 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Quantitative Hand Grip
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: ALSFRS-R
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Clinical Outcome at Day 14
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CF-301 Maximum Plasma Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CF-301 Area Under the Curve (AUC 0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of new HIV diagnoses
Endpoint domain: Mortality/survival
Primary endpoint: Affective state
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean cartilage T1rho relaxation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean cartilage T2 relaxation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean cartilage T1 relaxation time post gadolinium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Musculoskeletal Health Questionnaire (MSK-HQ)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Infection of novo persistent
Endpoint domain: Adverse events/effects
Primary endpoint: Pulmonary immune responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean Monthly Change in Number of Units of Healthier Foods
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Monthly Change in Number of Units of Less Healthy Foods
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Edinburgh Prenatal Depression Scale (EPDS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Interpersonal Support Evaluation List (ISEL)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Pharmacokinetic parameters of Midazolam, Rosiglitazone, and VX 770
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic parameters of Fluconazole and VX 770
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Sildenafil Plasma Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arthritis Complete Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective success defined as the absence of vaginal bulge
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Physiological Changes in Response to Cue-induced Craving
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability of Treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Discontinuation of Study Drug Due to Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Knee valgus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Single leg balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxygen consumption during bicycle exercise protocol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Gastrointestinal Tolerability Questionnaire (GITQ) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in number of participants achieving remission from Type II diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in number of participants achieving remission from Hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: change in visual rating of skin response (redness and oedema)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Proportion of patients with therapeutic failure
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical symptoms duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of infiltration rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of Support During Implementation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Difference in mm Squared of Cirrus HD-OCT Automated Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total number of individuals with tau present
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Functional imaging (fMRI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antibody Concentrations Against Pertussis Antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Concentration of NGAL in Urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Concentration of IL-18 in Urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Concentration of IL-18 in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of NGAL in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Phototoxic Reaction (Erythema Score)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of severe hypoglycaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sensitivity of Ga-68 HBED-CC PSMA for Detection of Nodal Metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Specificity of Ga-68 HBED-CC PSMA for Detection of Nodal Metastasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Positive Predictive Value (PPV) of Ga-68 HBED-CC PSMA for Detection of Nodal Metastasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Negative Predictive Value (NPV) of Ga-68 HBED-CC PSMA for Detection of Nodal Metastasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Daily Pain Diary
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in 30 second sit to stand measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean diurnal systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Childhood Health Assessment Questionnaire (CHAQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Scalp VAS Pruritus assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of self-monitoring step count
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Acceptability of PATH intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of diabetic patients whose principal ulcer will heal completely
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uptake of nutritional support rations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability of nutritional support
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Costs of monthly nutritional support rations
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Depression rating scale score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Regensburg Insomnia Scale (RIS)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Drinks per Week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drinks per Drinking Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Renal Function as Assessed by GFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage of Patients Whose Activated Clotting Time (ACT) is Prolonged Beyond 480 Seconds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: diagnostic yield of angiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient reported pain
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Change in neurosensory recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction of symptomatology associated with Generalized Anxiety Disorder
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Toxicities of Ontak administration
Endpoint domain: Adverse events/effects
Primary endpoint: Binge-Eating Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percutaneous oxygen saturation (SpO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ophthalmologic examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glycemic control (serum hemoglobin A1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline Body mass index (BMI) at 6-month
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline Glycated Haemoglobin (HbA1c) at 6-month
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes from baseline Systolic Blood Pressure (SBP) at 6-month
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in DUX4 Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percent articulatory accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Developed Anti-Romosozumab Antibodies
Endpoint domain: Adverse events/effects
Primary endpoint: Albumin-Adjusted Serum Calcium Concentrations by Visit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Intact Parathyroid Hormone (iPTH) Concentrations by Visit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: bone events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Correlation between PUV and SUV of breast malignancies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: NRS-Pain With Movement on POD 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total motile sperm (TMS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Tumor response rate (CR + PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Conners 3 Short Form
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Automatic Thoughts Questionnaires (ATQ)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Difference in Actual Blood Volume and Estimated Blood Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Health Economic Benefits
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: Functional HDL-C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Patient Perceived Health Status
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prevalence of musculoskeletal disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in serum levels of brain natriuretic peptide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of interventions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time to intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of additional visits to the Emergency Department
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Significant weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Multiscale entropy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in tumor size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: changes of retinal and choroidal thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Mean Methacholine Responsiveness (PC20)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Efficacy of topical application of NM 0.04%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Monthly incidence of antibodies against SARS-CoV-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes